IvelinRadkov
Delcath Systems (NASDAQ:DCTH) stock jumped 15% Tuesday after the corporate reported optimistic outcomes from a retrospective study of its Hepzato Kit within the remedy of sufferers with liver metastases from uveal melanoma.
The study, which was revealed within the Annals of Surgical Oncology, confirmed an general median progression-free survival of 15.4 months for sufferers who had obtained Hepzato Kit as a first-line remedy, in contrast with 8.8 months for many who had obtained immunotherapy and 9.2 months for different liver-directed therapies.
As a second-line remedy, these handled with Hepzato Kit had a median progression-free survival of twenty-two.2 months, versus 14.7 months for many who obtained immunotherapy and seven.5 months for different liver-directed therapies.
The study additionally confirmed considerably longer hepatic progression-free survival for many who obtained Hepzato Kit versus immunotherapy or different liver-directed therapies, based on an announcement.
Source: Seekingalpha
